Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Timing of return of results; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6,789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 7 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Pilocarpine, Ofloxacin, Prednisolone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Primary Open Angle Glaucoma
Interventions: OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication; Device · Drug
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Petaluma, California • Maryville, Tennessee

Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions: XO Genius; Dietary Supplement
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Hypertension Uncomplicated, Pre Hypertension
Interventions: High and low salt diets; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Melanie Maykin, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hypertension, Resistant to Conventional Therapy
Interventions: Minocycline Hydrochloride, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: iRF System Hepatic Denervation; Device
Lead sponsor: Metavention; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more

Conditions: Hypertension
Interventions: Modified Citrus Pectin (MCP) vs placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Surgery, Selective Laser Trabeculoplasty; Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Orthostatic Hypotension
Interventions: Droxidopa, Pyridostigmine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma
Interventions: MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cognitive Decline, Blood Pressure, Hypertension
Interventions: Clinical Support Decision Tool; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 70 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma
Interventions: Beacon Aqueous Microshunt; Device
Lead sponsor: MicroOptx; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Grand Junction, Colorado • Bloomington, Minnesota • Dayton, Ohio

Conditions: Obesity, Maternal, Hypertension in Pregnancy, Hypertension, Pregnancy-Induced, Diabetes, Overweight
Interventions: Family Check Up Heart, Family Check-Up; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Medication Adherence, High Blood Pressure, Diabetes
Interventions: Medication Adherence Partner, Electronic pill bottle; Behavioral · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension PAH
Interventions: Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008); Other · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Primary Aldosteronism, Hypertension
Interventions: Eplerenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension Stage 1
Interventions: brain natriuretic peptide, no-added salt diet; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions: Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pulmonary Artery Hypertension
Interventions: GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Chronic Kidney Diseases, Chronic Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Chronic Kidney Disease Stage 5, Hypertension
Interventions: Control-EDI, Intervention-EDI, Health coaching; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 6 more

Search by objective public record fields.

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States

Pilocarpine After Combined Cataract/Trabectome Surgery

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

The Impact of KETO5 XOGenius Beverage on Markers of Physiological and Neurocognitive Health

A Biomarker to Detect Salt Sensitivity

Furosemide vs. Placebo for Severe Antepartum Hypertension

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

Galectin-3 Blockade in Patients With High Blood Pressure

Effects of Selective Laser Trabeculoplasty

Droxidopa / Pyridostigmine in Orthostatic Hypotension

Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients

Preventing Cognitive Decline by Reducing BP Target Trial

Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma

Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children

Social Forces to Improve Statin Adherence (Study A)

Study of Intravenous ZMA001 in Healthy Subjects

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

B-type Natriuretic Peptide (BNP) in Human Hypertension

Determinants of Compliance With Glaucoma Therapy

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Controlling Hypertension Through Education and Coaching in Kidney Disease